Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIKE
2015-005398-18Phase 4Terminated
- Sponsor
- AbbVie Inc.
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of adalimumab in axial spondyloarthritis (axSpA) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Clinical disease activity at Week 32. Started Mar 2016; status: terminated.
02
Drugs
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2015-005398-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005398-18.